Loading...
Market
Will SLS-002 receive Fast Track designation from the FDA by December 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements or Seelos Therapeutics' press releases
Story
Seelos Therapeutics ($SEEL) Signs Agreement with USAMMDA to Evaluate SLS-002 for PTSD, Stock Surges 115.8%
Sep 24, 2024, 12:38 PM
Seelos Therapeutics ($SEEL) has announced the signing of a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate its intranasal ketamine, SLS-002, for the treatment of PTSD. This agreement includes the inclusion of SLS-002 in the U.S. Department of Defense’s M-PACT trial, which will begin dosing in the fourth quarter of 2024. The Phase II trial will assess the safety, efficacy, and tolerability of SLS-002 in active-duty service members and veterans. Following this announcement, Seelos Therapeutics' stock surged by 115.8% in pre-market trading.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Granted in 2024 • 25%
Granted in 2025 • 25%
Not granted by 2025 • 25%
Other designation received • 25%
Yes • 25%
No • 25%
Application submitted but not yet approved • 25%
Not applicable/Other • 25%
